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CLINICAL AND POPULATION SCIENCES
Burden of Stroke in Europe
Thirty-Year Projections of Incidence, Prevalence, Deaths, and Disability-Adjusted 
Life Years
Hatem A. Wafa , MPH*; Charles D.A. Wolfe, MD; Eva Emmett, MPH; Gregory A. Roth, MD; Catherine O. Johnson, PhD;  
Yanzhong Wang, PhD
BACKGROUND AND PURPOSE: Prediction of stroke impact provides essential information for healthcare planning and priority 
setting. We aim to estimate 30-year projections of stroke epidemiology in the European Union using multiple modeling 
approaches.
METHODS: Data on stroke incidence, prevalence, deaths, and disability-adjusted life years in the European Union between 
1990 and 2017 were obtained from the global burden of disease study. Their trends over time were modeled using 3 
modeling strategies: linear, Poisson, and exponential regressions―adjusted for the gross domestic product per capita, which 
reflects the impact of economic development on health status. We used the Akaike information criterion for model selection. 
The 30-year projections up to 2047 were estimated using the best fitting models, with inputs on population projections 
from the United Nations and gross domestic product per capita prospects from the World Bank. The technique was applied 
separately by age-sex-country groups for each stroke measure.
RESULTS: In 2017, there were 1.12 million incident strokes in the European Union, 9.53 million stroke survivors, 0.46 million 
deaths, and 7.06 million disability-adjusted life years lost because of stroke. By 2047, we estimated an additional 40 000 
incident strokes (+3%) and 2.58 million prevalent cases (+27%). Conversely, 80 000 fewer deaths (–17%) and 2.31 
million fewer disability-adjusted life years lost (–33%) are projected. The largest increase in the age-adjusted incidence 
and prevalence rates are expected in Lithuania (average annual percentage change, 0.48% and 0.7% respectively), and the 
greatest reductions in Portugal (–1.57% and –1.3%). Average annual percentage change in mortality rates will range from 
−2.86% (Estonia) to −0.08% (Lithuania), and disability-adjusted life years’ from −2.77% (Estonia) to −0.23% (Romania).
CONCLUSIONS: The number of people living with stroke is estimated to increase by 27% between 2017 and 2047 in the 
European Union, mainly because of population ageing and improved survival rates. Variations are expected to persist between 
countries showing opportunities for improvements in prevention and case management particularly in Eastern Europe.
Key Words: global burden of disease ◼ health status ◼ incidence ◼ prevalence ◼ stroke
In the European Union (EU), stroke is the second most common cause of death and a leading cause of adult dis-ability.1 It affects ≈1.1 million inhabitants of Europe every 
year2 and causes 440 000 deaths.3 In 2017, the cost asso-
ciated with stroke was estimated at €45 billion, including 
direct and indirect costs of care provision and productivity 
loss.1 As populations continue to grow and live to an older 
age, stroke events and their long-term sequelae, and the 
corresponding costs, are expected to increase dramati-
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valuable for medium- and long-term planning and organi-
zation of stroke services and prevention activities.
Several authors have calculated projections of stroke 
for a specific region,5 country,6–10 or internationally,11–13 
combining demographic projections with estimated future 
incidence and mortality rates. Those estimates were either 
based on the most recent age-specific rates5,9 or obtained 
by extrapolation from past trends.6–8,10–12 In a 2006 study,11 
investigators used demographic projections up to 2025 
together with WHO estimates of incidence rates to project 
incidence of stroke in all EU countries, plus Iceland, Nor-
way, and Switzerland.14 They forecasted an increase in the 
number of incident stroke events from 1.1 million in 2000 
to over 1.5 million in 2025 if the 2000’s rates remained 
stable, and a lower but still significant increase to around 
1.35 million if rates declined by 2% every 5 years. This 
approach predicts the number of stroke events that would 
arise from demographic changes with an arbitrary assump-
tion about epidemiological trends over time. Incorporating 
significant predictors of stroke risk (eg, hypertension, smok-
ing, and alcohol consumption) into the model can help to 
reduce uncertainty and improve reliability. However, scarcity 
of these kinds of data and their future projections across 
the EU limit the feasibility of such an approach. Incorporat-
ing a distal indicator could be an alternative. Previous GBD 
studies projecting heath outcomes have shown that mea-
sures of economic development such as the gross domes-
tic product per capita (GDP) could be a useful proxy for 
the changes in risk factors and their management, socio-
economic status, and education, among other time-varying 
indicators.13,15,16
We aimed to use GDP as a holistic predictor of stroke 
events and outcomes to project not only stroke-associ-
ated incidence but also prevalence, deaths, and disability-
adjusted life years (DALYs) lost over the next 30 years, 
after accounting for past trends, both overall in the EU and 
in individual countries. We combined GDP estimates, pre-
pared by the World Bank, with GBD data and the United 
Nations’ population projections to fit models that would 
(1) best describe the observed time-trends between 1990 
and 2017 and (2) predicts future events up until 2047.
METHODS
All GBD data and materials have been made publicly avail-
able at the GBD Network and can be accessed at http://ghdx.
healthdata.org/gbd-results-tool.
Projection Methods
Separate projection models by sex and age groups, in 5-year 
bands, were developed for 28 European countries to estimate 
time-trends in 4 stroke measures: incidence, prevalence, deaths, 
and DALYs lost. Each measure was modeled as a rate using 
historically observed data between 1990 and 2017. Instead of 
modeling the effects of multiple covariates, from the limited data 
that are available, our models predict stroke epidemiological pro-
file as a function of 2 distal variables, which showed clear his-
torical relationship with the outcome measures. These were time 
in years, a proxy measure which potentially reflects the effect 
of medical advances, and the average income per capita, mea-
sured as GDP and adjusted for purchasing power parity in 2011 
US Dollars, a collective measure which indicates the indirect 
impact of economic development on health status. The former 
variable (time) captures the effects of accumulating knowledge 
and medical development, allowing the implementation of more 
effective health interventions, both preventive and curative, at 
constant levels of income.15 The latter variable (GDP) has shown 
to be a distant, yet strong, predictor of stroke outcomes.15,17,18
Three regression models were performed: linear, expo-
nential, and Poisson. The Akaike information criterion was 
used to compare the fit of these formulations. In agreement 
with the Global Burden of Disease (GBD) methodology,15,16 
model selection suggested that exponential regressions pro-
vided the best fit for all measures in almost all age-sex-cohort 
groups and were therefore used to develop the final models 
(models parameters are detailed in Tables I and II in the Data 
Supplement).
The final regression equations took the following form:
lnR C lnY Ta k i a k i, , , ,= + +β β1 2
Where Ca k i, ,  is a constant term; Ra k i, ,  is the outcome rate for 
age group a, sex k, and country i; and Y and T denote GDP per 
person and time in years, respectively. Those age-sex-country-
specific models used 2018 to 2047 GDP inputs from the 
World Bank to generate 30-year forecasts of rates beyond the 
reference year (2017). The methods used are generally similar 
to previous GBD studies,13,15,16 with more systematic proce-
dure for model selection in addition to using updated inputs 
of stroke-specific data not only for incidence and mortality but 
also prevalence and DALYs.
Our forecast projected the absolute numbers of stroke inci-
dence, prevalence, deaths, and DALYs by multiplying the pro-
jected rates in 2018 to 2047 by the corresponding age-, sex-, 
year-, and country-specific population projections. Estimates 
were then aggregated for presentation of the results in indi-
vidual countries and overall in the EU. In addition, we calcu-
lated the absolute number of events that would occur if rates 
remained stable (baseline), decreased annually by 1% (opti-
mistic), and increased annually by 1% (pessimistic) with refer-
ence to the 2017 observed rates. We reported age-adjusted 
incidence and mortality rates per 100 000 person-years, and 
prevalence and DALYs per 10 000 people using the direct 
method of standardization and the updated European Standard 
Population (2013) as a reference.19 Finally, the average annual 
percentage changes (AAPC) in the crude and age-adjusted 
rates were calculated by dividing the relative change between 
2017 and 2047 by the number of years. All analyses were per-
formed using the statistical software R version 3.5.0.
Nonstandard Abbreviations and Acronyms
DALY disability-adjusted life years
GDP gross domestic product per capita
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Model Validation and Forecasting Analysis
We ran internal model validation and forecasting analysis com-
paring our methods to the most widely used demographic 
approach.20 We fitted our models using only data from 1990 
to 2007 to forecast stroke outcomes during 2008 to 2017. 
Out-of-sample validation forecasts for 2008 to 2017 were 
then compared with the observed data in the same period. 
Accuracy was assessed over the test period using the root-
mean-squared error.
Despite the scarcity of risk factors data, additional models 
were fitted in 2 countries (Sweden and the United Kingdom) 
where more complete data could be obtained from GBD dur-
ing the study period. In these risk factors models, the changing 
prevalence of diabetes mellitus, hypertension, and atrial fibrilla-
tion were incorporated as direct predictors of stroke outcomes. 
Again, models were fitted to 1990 to 2007 data, then informa-
tion on demography and risk factors during 2008 to 2017 was 
used to guide the forecasts during that period. Results were 
then compared to our models’ using GDP as a distant predictor 
of stroke outcomes (Figures I and II in Data Supplement).
Data Sources
We used the results of GBD 2017 to estimate patterns of 
stroke incidence, prevalence, deaths, and DALYs between 
1990 and 2017.21 Count data were obtained on a national 
scale for 28 EU countries by age and sex groups. A wide range 
of data sources was used to estimate these measures which 
are described in detail previously.22–25 In brief, for the selected 
countries, systematic review of the literature was performed to 
identify ideal population-based studies. Only studies that used 
the WHO’s definition of stroke26 with complete case ascertain-
ment were included. Death registration data were provided to 
the WHO by Member States. In addition, population-based epi-
demiological studies, disease registers, and surveillance sys-
tems contributed to estimation of stroke mortality.13 Estimation 
of DALYs was based on calculation of 2 components: years 
of life lost because of death, and years lived with disability. 
Detailed methodology is described elsewhere.27,28 One DALY 
represents a year of healthy life lost. All GBD data sources can 
be accessed via the GBD 2017 Data Input Sources Tool.
Population estimates and projections for each country 
were obtained from the United Nations (UN) Department of 
Economic and Social Affairs/Population Division.29 Future pros-
pects were made according to a framework which accounts for 
the 3 demographic components of change―fertility, mortal-
ity, and international migration.30 We used the medium-variant 
assumption in our analyses, which assumes a decline in the 
fertility for countries where large families are still prevalent and 
a continuous decline in death rates throughout the age range. 
Historical and future indicators of economic development, as 
measured in GDP per capita, were obtained from the World 
Bank and the OECD online toolkits.31,32 All data are deidenti-
fied and publicly available, and hence no ethics approval was 
necessary. Interactive online tools are also available to explore 
all data sources in detail.
GBD data on stroke incidence, prevalence, deaths, and 
DALYs were complete for all countries across the years (1990–
2017). GDP data from the World Bank were missing for a few 
countries in the early years: 1990 to 1991 for Slovakia; 1990 
to 1994 for Croatia, Estonia, Latvia, Lithuania, and Slovenia; 
and 1990 to 2000 for Malta. Autoregressive integrated moving 
average models were fitted to interpolate these missing values.
RESULTS
In 2017, ≈509 million people were residents in the EU. 
There were an estimated 1.12 million cases of incident 
stroke, 9.53 million prevalent stroke cases, 0.46 million 
stroke deaths, and 7.06 million DALYs lost (Table). By 
2047, the population size is expected to remain relatively 
stable; however, there will be an additional 40 000 inci-
dent stroke cases (3% increase) and 2.58 million preva-
lent cases (27% increase). This is largely because of the 
projected changes in the population age structure, and, 
in particular, by an increase in the number of residents 
aged ≥70 years old (comprising 23% of the population in 
2047 compared with 14% in 2017), in which stroke risk 
is the highest. Conversely, the declining trends in deaths 
and DALYs between 1990 and 2017 are expected to 
continue through 2047 (Figure 1), resulting in ≈80 000 
fewer deaths (17% reduction) and 2.31 million fewer 
DALYs (33% reduction). The age-adjusted rates on the 
other hand for the 4 epidemiological measures are pre-
dicted to decline: 26% for incidence, 9% for prevalence, 
and 55% for both mortality and DALYs lost.
Figure 2 illustrates the percentage changes between 
2017 and 2047 in the counts of the EU population and 
stroke incidence, prevalence, deaths, and DALYs by age 
cohorts. Greater magnitude of change for older age groups 
is demonstrated for all measures, which reflects population 
aging and a larger, rising burden of stroke in older people. 
The expected increase in incident and prevalent stroke 
cases will be exclusive to those aged ≥70 years, whereas 
a reduction will be observed in the younger age groups. On 
the other hand, mortality and DALYs lost because of stroke 
will decline in all ages except people ≥90 years old.
A breakdown of the absolute numbers by countries 
are provided in Figures III through VI in Data Supple-
ment. While several countries will experience a varying 
increase in numbers of incident strokes, others will have 
either no change or a decrease in numbers (Figure III in 
the Data Supplement). All but 7 countries (Estonia, Por-
tugal, Italy, Hungary, Latvia, Romania, and Czech Repub-
lic) will experience an increase in the number of stroke 
survivors, and almost all countries will see a decline in the 
number of deaths and DALYs lost.
Projected crude and age-adjusted rates give account 
of future stroke epidemiology regardless of variations in 
population size and/or age structure. Figure 3 demon-
strates the estimated AAPC in the crude rates of stroke 
between 2018 and 2047. Most countries will continue 
past trends of increasing crude incidence and preva-
lence rates, while mortality and DALYs lost will decrease. 
Nevertheless, the age-adjusted rates are estimated to 
decline over the next decades in almost all countries, 
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In 2047, our models predict age-adjusted rates ranging 
from 467 (Lithuania) to 92/100 000 (Italy) for incidence, 
from 428 (Lithuania) to 73/10 000 (Italy) for prevalence, 
from 267 (Bulgaria) to 10/100 000 (Austria) for deaths, 
and from 429 (Romania) to 23/10 000 (Austria) for 
DALYs lost (Figures VII through X in the Data Supple-
ment). Between 2018 and 2047, the age-adjusted AAPC 
will range, for incidence, from –1.57 % (Portugal) to 
0.48% (Lithuania); prevalence, –1.3 (Portugal) to 0.7% 
(Lithuania); deaths, –2.86% (Estonia) to 0.08% (Lithua-
nia); and DALYs, –2.77% (Estonia) to –0.23% (Romania).
Comparison of out-of-sample prediction and past data 
are shown in Figure 5. Results show that our models had 
lower prediction errors than Lee-Carther approach dur-
ing the test period, indicating superior performance. For 
instance, our methods predicted stroke incidence dur-
ing 2008 to 2017 with a mean error of 0.011 million 
cases whereas Lee-Carter mean error was 0.062 mil-
lion strokes. Furthermore, our forecasts during this test 
period were similar to those obtained from risk factors 
models in the United Kingdom and Belgium (Figures I 
and II, respectively in the Data Supplement).
DISCUSSION
This study provides country-specific projections of stroke 
burden in the EU up to 2047 using multiple modeling 
techniques building on GBD estimates. Unlike conven-
tional projection approaches, not only did the current 
analysis account for demographic and epidemiologi-
cal changes, but also prospects of economic develop-
ment (measured in GDP per capita), a proxy measure 
for the complex changes in lifestyle, risk factors, and 
their management, and other environmental and behav-
ioral factors.15,17,18 Previous GBD investigators carried 
out projections of mortality and DALYs for disease-spe-
cific13,33 and compiled clusters of cause-of-death,15,16 
and presented the results on regional and global lev-
els.13,15,16 In the current study, we analyzed 4 epidemio-
logical measures for stroke in 28 EU countries, applying 
more rigourous model selection methodology, and using 
detailed and updated information to guide projections 
and produce more reliable estimates. Between 2017 
and 2047, we predict an increase in the absolute count 
of stroke events in the EU by 3% (from 1.12 to 1.16 
million), and stroke survivors by 27% (9.53 to 12.11 mil-
lion), despite a projected decline in the corresponding 
age-standardized rates. Deaths and DALYs because of 
stroke are expected to decrease by 17% (0.46–0.38 
million) and 33% (7.06–4.75 million), respectively.
Previous studies conducted in Europe5–10,34 and other 
high-income countries35–37 also predicted rises in stroke 
numbers. The Stroke Alliance for Europe anticipated a 
34% increase in incident stroke events between 2015 
and 2035.34 In contrast, the current study forecasts a 
Table. Changes in Population Count and Stroke Incidence, Prevalence, Deaths, and DALYs in the EU Between 2017 and 2047
2017 2027 2047
Relative Change (vs 2017)
2027 2047
Population count
 Overall 508.94 512.48 505.3 1.01 0.99
 ≥70 y 71.52 86.85 116.34 1.21 1.63
Incidence
 Count 1.12 (1.08–1.16) 1.14 (1.08–1.21) 1.16 (1.02–1.33) 1.02 (1–1.04) 1.03 (0.95–1.15)
 Crude rate* 219.4 (212–227) 223.3 (211–237) 228.6 (202–263) 1.02 (0.99–1.04) 1.04 (0.96–1.16)
 Adjusted rate* 211.7 (204–219) 189.5 (179–201) 156.3 (140–177) 0.9 (0.88–0.92) 0.74 (0.68–0.81)
Prevalence
 Count 9.53 (9.22–9.85) 10.4 (9.79–11.07) 12.11 (10.58–14.4) 1.09 (1.06–1.12) 1.27 (1.15–1.46)
 Crude rate† 187 (181–194) 203 (191–216) 240 (209–285) 1.08 (1.06–1.12) 1.28 (1.16–1.47)
 Adjusted rate† 182 (176–188) 174 (164–186) 165 (145–194) 0.96 (0.93–0.99) 0.91 (0.83–1.03)
Deaths
 Count 0.46 (0.44–0.49) 0.42 (0.38–0.46) 0.38 (0.31–0.54) 0.91 (0.87–0.95) 0.83 (0.7–1.11)
 Crude rate* 90.7 (86.1–95.6) 81.6 (74.2–90.4) 75.9 (60.6–106.9) 0.9 (0.86–0.95) 0.84 (0.7–1.12)
 Adjusted rate* 85 (80.7–89.6) 63.6 (57.9–70.4) 38.3 (30.6–53.2) 0.75 (0.72–0.79) 0.45 (0.38–0.59)
DALYs
 Count 7.06 (6.75–7.39) 6.07 (5.6–6.61) 4.75 (3.91–6.11) 0.86 (0.83–0.89) 0.67 (0.58–0.83)
 Crude rate† 139 (133–145) 118 (109–129) 94 (77–121) 0.85 (0.82–0.89) 0.68 (0.58–0.83)
 Adjusted rate† 134 (128–140) 99 (92–108) 60 (49–76) 0.74 (0.72–0.77) 0.45 (0.39–0.55)
Count data are in millions. Age-adjusted rates are estimated with reference to the 2013 European Standard Population. DALY indicates disability-adjusted life years.
*Per 100 000 person-year.
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modest increase by 3% between 2017 and 2047. Meth-
odological differences is likely to explain such disparity. 
Stroke Alliance for Europe and other previous projection 
studies were either based on a stable rates assumption 
or linear extrapolation of past trends. The former is likely 
to overestimate stroke events whereas the latter could 
lead to implausible increase/decrease in rates and the 
subsequent counts, and therefore these approaches 
are suboptimal. Furthermore, Stroke Alliance for Europe 
used the Eurostat population data which predict sig-
nificant population ageing and growth, whereas the UN 
data, used in the current study, project a remarkable 
aging but a relatively stable population size. On the other 
hand, the age-adjusted incidence rates produced by our 
models are not divergent from past trends, an AAPC of 
–0.87% between 2018 and 2047 versus –1% reported 
in developed countries during 1970 to 2008.38 Truelsen 
et al11 used an arbitrary change of ±2%/5 years to proj-
ect a range of stroke incidence in the EU between 2000 
and 2025. The results, however, appeared to overesti-
mate stroke events―the projected figures are larger 
than those already observed during 2000 to 2017. For 
instance, in 2015, ≈1.28 million new strokes were pro-
jected even under the optimistic scenario (−2%/5 years), 
which is still larger than the 1.1 million cases reported by 
GBD for the same year.21
By 2047, 2.4% of the EU population are estimated to 
have had a stroke―an increase of 28% compared with 
2017 which may be explained as follows. As demograph-
ics change over time, older people will constitute a larger 
proportion of the EU population despite the relatively 
stable overall count projected for the future. Eventually, 
this factor will contribute greater number of patients with 
stroke who will have a greater chance of surviving the ini-
tial event for 2 reasons. First, many of these strokes will 
be milder in nature because of the ongoing advances and 
widespread implementation of primary prevention strate-
gies,39,40 and second, patients in the future are more likely 
to receive better care and treatment both in the acute 
and long-term stages after stroke. Consequently, a shift 
in stroke burden from mortality to morbidity is likely to be 
observed in the future. If disability levels among stroke 
survivors remain unchanged over the next decades, then 
the demand for rehabilitation and long-term care will 
increase by 27% in the EU. Economically, this increased 
demand will have to be borne by a smaller working age 
population (currently defined as those aged 15–64),41 
which will in turn have implications in terms of increased 
workload and per capita financial burden. While several 
studies predict rising future costs of stroke,8,9 there is 
some evidence that certain treatments (eg, thromboly-
sis, early supported discharge) can contribute to con-
taining these costs.8,42
For most EU countries, significant declines in stroke 
mortality have been reported since 1970.43–45 One study 
calculated an AAPC of −2.7% in the age-adjusted mor-
tality rate between 1980 and 2016 across Europe,45 
and a range of −1% and −4% was reported in seven 
Western European countries between 1980 and 2005.12 
These estimates are comparable to our historical AAPC 
of –3.3% observed during 1990 to 2017, and our pro-
jected figure of −1.8% within the next 30 years (2018–
2047). Indeed, past improvements in mortality are linked 
Figure 1. Historical trends and future trajectories of 
stroke incidence, prevalence, deaths, and disability-
adjusted life years (DALYs) in the European Union since 
1990 and up to 2047.
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to better survival rates, partly because of advances in 
therapeutic options and acute management (eg, throm-
bolysis treatment and stroke unit care).46,47 Wider appli-
cation of these approaches together with implementation 
of newer treatment methods (eg, thrombectomy and 
centralized care provision)48–50 might therefore bring 
further reductions. However, mortality is not only deter-
mined by survival and case-fatality but also by incidence 
rate. Although it is difficult to ascertain which mea-
sure has a greater influence on mortality in absence of 
Figure 2. Projected change in population, incidence, prevalence, deaths, and disability-adjusted life years disability-adjusted 
life years (DALYs) count by age group in the European Union (2047 vs 2017).
Figure 3. Projected average annual 
percentage change in the crude rates 
of incidence, prevalence, death, and 
disability-adjusted life years (DALYs) 
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reliable survival data, the decline in stroke incidence and 
mortality suggests a greater contribution of incidence on 
mortality reduction.13,38
Variation across EU countries in stroke incidence, 
prevalence, deaths, and DALYs has been documented in 
the past2,43,45,51 and is noted in the current study. An East-
West gradient will be observed in the future, and the 
most striking increase in the age-adjusted rate of stroke 
prevalence is expected in Lithuania (AAPC, 0.7%). It is 
also the only EU country which is predicted to witness 
an increase in stroke incidence (0.48%). Portugal on the 
other hand is estimated to have the greatest reductions 
in incidence (−1.57%) and prevalence (−1.3%). Pos-
sible improvement in health systems, case detection, and 
clinical diagnosis might have contributed to the apparent 
changes in stroke incidence and subsequent prevalence 
rates. However, differences in exposure to cardiovascu-
lar risk factors over time and their level of control could 
also account for the observed and projected geographic 
variations. For instance, Portugal achieved one of the 
greatest reductions in smoking rates between 1990 and 
2014, whereas Lithuania is the only EU country which 
had a remarkable increase in alcohol consumption rates 
during the same period.52 In Estonia, significant reduc-
tions in stroke mortality and DALYs were observed 
(1990–2017) and are estimated to extrapolate into the 
future (AAPC, −2.86% and −2.77%, respectively). It is 
also one of the countries where prescription of antihy-
pertensive and lipid-modifying drugs soared between 
2000 and 2013,52 which might reflect improved primary 
and secondary prevention and hence reduced incidence 
and case-fatality. While some countries (eg, Portugal and 
Greece) had relatively higher rates of stroke incidence 
in the past and therefore larger capacity for improve-
ment and steeper declines (1990–2017), others, such 
as Italy, France, and the United Kingdom, achieved fur-
ther reductions from already lower rates. On the other 
hand, most Eastern European countries (eg, Lithuania 
and Romania), despite having the highest rates in the 
past, achieved modest declines, or even increases, which 
might indicate less efficient interventions. Such histori-
cal patterns will reflect in the future and are expected 
to persist. Our projections give an indication of the rates 
that could potentially be achieved across the EU with 
sustained public health efforts and suggest that further 
improvement is possible in most countries.
The current analysis combines large, international, 
and standardizsed datasets that are highly comparable; 
however, we emphasise that our estimates are based 
on a set of assumptions about future demographic, 
epidemiological, and economic trends. Therefore, our 
projections are simply visioning what the future may 
unfold if these assumptions hold true, and we empha-
size that they need to be interpreted with this in mind. 
Figure 4. Projected average annual 
percentage change in the age-
standardized rates of incidence, 
prevalence, death, and disability-
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We did not take explicit account of trends in major 
stroke risk factors (eg, hypertension, smoking, and 
poor diet) because of scarcity of the data. If exposure 
to stroke risk factors increase, rather than decrease, 
with economic development, then our projections will 
be underestimates. More comprehensive projection 
models that specifically take account of these risk fac-
tors with further stratification by ethnic groups might 
be valuable. A recent GBD study developed a novel 
forcasting model which incorporates the relation-
ships between the independent drivers of health cap-
tured within GBD.33 The model was used to estimate 
all-cause and disease-specific mortality, years of life 
lost, and life expectancy up until 2040, and the results 
were presented on regional and global scales. Adopt-
ing such an approach could be useful to better fore-
cast other important disease-specific measures like 
incidence, prevalence, and DALYs by incorporating 
relevant and vital inputs to improve projections accu-
racy. We finally acknowledge that data quality may vary 
across the EU, which could make some estimates less 
certain than others particularly in Eastern European 
countries where epidemiological studies are less fre-
quent.38 Nevertheless, this study provides a useful per-
spective on population health trends, which could have 
implications on health policy and priority setting.
In conclusion, the absolute burden of stroke was 
increasing and is expected to continue to increase over 
the next 30 years in most EU countries, particularly in 
Eastern states. With an estimated 27% increase in the 
number of people surviving a stroke in Europe, in com-
bination with a reduced proportion of people at work-
ing ages, there is an imperative to make greater efforts 
to prevent stroke. This would be the most effective 
strategy to reduce the anticipated financial and logistic 
challenges facing countries with an already stressed 
healthcare systems.
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